Ashton Thomas Private Wealth LLC Increases Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Ashton Thomas Private Wealth LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 5.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 16,358 shares of the company’s stock after buying an additional 798 shares during the quarter. Eli Lilly and Company makes up about 0.8% of Ashton Thomas Private Wealth LLC’s investment portfolio, making the stock its 28th largest holding. Ashton Thomas Private Wealth LLC’s holdings in Eli Lilly and Company were worth $14,492,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in Eli Lilly and Company by 19.6% during the first quarter. China Universal Asset Management Co. Ltd. now owns 9,897 shares of the company’s stock valued at $7,699,000 after purchasing an additional 1,620 shares during the period. William Blair Investment Management LLC bought a new stake in Eli Lilly and Company during the first quarter valued at about $1,540,000. Koshinski Asset Management Inc. lifted its position in shares of Eli Lilly and Company by 27.2% in the first quarter. Koshinski Asset Management Inc. now owns 4,513 shares of the company’s stock valued at $3,511,000 after acquiring an additional 965 shares in the last quarter. Patton Fund Management Inc. boosted its stake in shares of Eli Lilly and Company by 73.2% in the first quarter. Patton Fund Management Inc. now owns 8,979 shares of the company’s stock worth $6,985,000 after acquiring an additional 3,794 shares during the period. Finally, BHK Investment Advisors LLC grew its position in shares of Eli Lilly and Company by 55.0% during the first quarter. BHK Investment Advisors LLC now owns 1,558 shares of the company’s stock worth $1,212,000 after purchasing an additional 553 shares in the last quarter. 82.53% of the stock is owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Down 0.6 %

Shares of NYSE:LLY opened at $827.50 on Tuesday. The firm has a market capitalization of $785.56 billion, a PE ratio of 90.09, a price-to-earnings-growth ratio of 3.15 and a beta of 0.43. The business has a 50 day simple moving average of $893.78 and a two-hundred day simple moving average of $870.11. Eli Lilly and Company has a 1 year low of $561.65 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Wednesday, October 30th. The company reported $1.18 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). Eli Lilly and Company had a net margin of 20.48% and a return on equity of 71.08%. The business had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter in the previous year, the firm earned $0.10 EPS. Eli Lilly and Company’s revenue was up 20.4% compared to the same quarter last year. On average, equities analysts predict that Eli Lilly and Company will post 13.21 EPS for the current year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Friday, November 15th will be given a $1.30 dividend. The ex-dividend date of this dividend is Friday, November 15th. This represents a $5.20 annualized dividend and a yield of 0.63%. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on LLY shares. JPMorgan Chase & Co. increased their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the company an “overweight” rating in a report on Friday, September 13th. BMO Capital Markets lifted their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Bank of America decreased their target price on Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating on the stock in a research report on Thursday, October 31st. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a research report on Thursday, September 5th. Finally, Berenberg Bank boosted their price target on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,008.41.

Insiders Place Their Bets

In related news, CAO Donald A. Zakrowski sold 900 shares of the stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $803.38, for a total value of $723,042.00. Following the transaction, the chief accounting officer now owns 5,480 shares of the company’s stock, valued at $4,402,522.40. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.